雜志介紹

Journal Of Chemotherapy雜志介紹

《Journal Of Chemotherapy》是一本以English為主的未開(kāi)放獲取國(guó)際優(yōu)秀期刊，中文名稱化療雜志，本刊主要出版、報(bào)道醫(yī)學(xué)-INFECTIOUS DISEASES領(lǐng)域的研究動(dòng)態(tài)以及在該領(lǐng)域取得的各方面的經(jīng)驗(yàn)和科研成果，介紹該領(lǐng)域有關(guān)本專業(yè)的最新進(jìn)展，探討行業(yè)發(fā)展的思路和方法，以促進(jìn)學(xué)術(shù)信息交流，提高行業(yè)發(fā)展。該刊已被國(guó)際權(quán)威數(shù)據(jù)庫(kù)SCIE收錄，為該領(lǐng)域相關(guān)學(xué)科的發(fā)展起到了良好的推動(dòng)作用，也得到了本專業(yè)人員的廣泛認(rèn)可。該刊最新影響因子為1.9，最新CiteScore 指數(shù)為3.7。

本刊近期中國(guó)學(xué)者發(fā)表的論文主要有：

• Using Monte Carlo simulation to determine optimal dosing regimen for cefetamet sodium for injection.

  Author: Li C, Sun J, Miao J, Qin Y, Wang Y, Yu R, Xiao Y.

• Efficacy and safety of biapenem in treatment of infectious disease: a meta-analysis of randomized controlled trials.

  Author: Pei G, Yin W, Zhang Y, Wang T, Mao Y, Sun Y.

• NOB1 expression predicts early response to cisplatin-based chemotherapy in patients with advanced non-small cell lung cancer.

  Author: Liu K, Chen HL, Gu MM, You QS.

• Radiotherapy combined with chemotherapy versus radiotherapy alone for early stage nasal natural killer/T-cell lymphoma: a meta-analysis.

  Author: Zhang B, Zhu F, Liu X, Zhao J, Li M, Li Y, Huang J, Zou L, Chang Q.

英文介紹

Journal Of Chemotherapy雜志英文介紹

The Journal of Chemotherapy is an international multidisciplinary journal committed to the rapid publication of high quality, peer-reviewed, original research on all aspects of antimicrobial and antitumor chemotherapy.

The Journal publishes original experimental and clinical research articles, state-of-the-art reviews, brief communications and letters on all aspects of chemotherapy, providing coverage of the pathogenesis, diagnosis, treatment, and control of infection, as well as the use of anticancer and immunomodulating drugs.

Specific areas of focus include, but are not limited to:

· Antibacterial, antiviral, antifungal, antiparasitic, and antiprotozoal agents;

· Anticancer classical and targeted chemotherapeutic agents, biological agents, hormonal drugs, immunomodulatory drugs, cell therapy and gene therapy;

· Pharmacokinetic and pharmacodynamic properties of antimicrobial and anticancer agents;

· The efficacy, safety and toxicology profiles of antimicrobial and anticancer drugs;

· Drug interactions in single or combined applications;

· Drug resistance to antimicrobial and anticancer drugs;

· Research and development of novel antimicrobial and anticancer drugs, including preclinical, translational and clinical research;

· Biomarkers of sensitivity and/or resistance for antimicrobial and anticancer drugs;

· Pharmacogenetics and pharmacogenomics;

· Precision medicine in infectious disease therapy and in cancer therapy;

· Pharmacoeconomics of antimicrobial and anticancer therapies and the implications to patients, health services, and the pharmaceutical industry.